<unk>  has been termed a “multichannel blocker”. However, it is unclear which channel(s) play a pivotal role in its success. Thus,<unk> 's actions at the cellular level are controversial, with most studies suggesting an inhibition in multiple outward potassium currents including rapid delayed rectifier, slow delayed rectifier and ACh-activated inward rectifier. It is also believed to reduce inward rapid Na current and L-type Ca channels. The reduction in K current in some studies was shown to be due to the inhibition of the K-ACh channel or associated GTP-binding proteins. Reduction of K+ current by 69% led to increased AP duration and increased effective refractory periods, thus shown to suppress pacemaker potential of the SA node and return patients to a normal heart rhythm. In a European trial, the average time to recurrence of an arrhythmia was 41 days in the placebo group vs. 96 days in the<unk>  group (similar results obtained in the non-European trial, 59 and 158 days respectively).
Dronedarone
Colestilan
Digitoxin
Metandienone
Amiodarone
Carteolol
Digoxin
Nebivolol